Combining TRT with EGFR-TKIs significantly improves PFS and OS in EGFR-mutated oligo-organ metastatic NSCLC patients compared to EGFR-TKIs alone. The study suggests personalized treatment approaches, ...

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...

BERLIN — Re-treatment with an anti-epidermal growth factor receptor (EGFR) agent is effective in patients with chemorefractory metastatic colorectal cancer (mCRC) with RAS and BRAF wild-type tumors ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and ...

Lung cancer is the leading cause of cancer mortality worldwide, resulting in 1.8 million deaths each year, with NSCLC accounting for 80 to 85 percent of all cases. 3,4 Of patients with EGFR-mutated ...

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Understanding eGFR and uPCR is vital for managing IgA nephropathy to predict kidney health, guide treatment, and work ...